1
|
Carestia E, Di Giuseppe F, Kazemi M, Ramahi M, Priyadarshi U, Giuliani P, De Francesco P, Schips L, Di Ilio C, Ciccarelli R, Di Iorio P, Angelucci S. Significant Changes in Low-Abundance Protein Content Detected by Proteomic Analysis of Urine from Patients with Renal Stones After Extracorporeal Shock Wave Lithotripsy. BIOLOGY 2025; 14:482. [PMID: 40427671 DOI: 10.3390/biology14050482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2025] [Revised: 04/18/2025] [Accepted: 04/20/2025] [Indexed: 05/29/2025]
Abstract
Extracorporeal shock wave lithotripsy (ESWL), although a highly effective method for the treatment of kidney stones, can cause significant kidney damage. Since urinary protein composition directly reflects kidney function, proteomic analysis of this fluid may be useful to identify changes in protein levels induced by patient exposure to ESWL as a sign of kidney damage. To this end, we collected urine samples from 80 patients with nephrolithiasis 2 h before and 24 h after exposure to ESWL, which were concentrated and subsequently processed with a commercially available enrichment method to extract low-abundance urinary proteins. These were then separated by 2D electrophoresis and subsequently analyzed by a proteomic approach. A large number of proteins were identified as being related to inflammatory, fibrotic, and antioxidant processes and changes in the levels of some of them were confirmed by Western blot analysis. Therefore, although further experimental confirmation is needed, our results demonstrate that ESWL significantly influences the low urinary protein profile of patients with nephrolithiasis. Notably, among the identified proteins, matrix metalloproteinase 7, alpha1-antitrypsin, and clusterin, as well as dimethyl arginine dimethyl amino hydrolase 2 and ab-hydrolase, may play an important role as putative biomarkers in the monitoring and management of ESWL-induced renal damage.
Collapse
Affiliation(s)
- Elena Carestia
- Center for Advanced Studies and Technologies (CAST), University "G. d'Annunzio" of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
- Department of Sciences, 'G d'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
| | - Fabrizio Di Giuseppe
- Center for Advanced Studies and Technologies (CAST), University "G. d'Annunzio" of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
- Department of Innovative Technologies in Medicine and Dentistry, University "G. d'Annunzio" of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| | - Mohammad Kazemi
- Center for Advanced Studies and Technologies (CAST), University "G. d'Annunzio" of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
- Department of Aging Medicine and Sciences (DMSI), 'G d'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
| | - Massoumeh Ramahi
- Center for Advanced Studies and Technologies (CAST), University "G. d'Annunzio" of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
- Department of Aging Medicine and Sciences (DMSI), 'G d'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
| | - Uditanshu Priyadarshi
- Center for Advanced Studies and Technologies (CAST), University "G. d'Annunzio" of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
- Department of Aging Medicine and Sciences (DMSI), 'G d'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
| | - Patricia Giuliani
- Department of Medical, Oral and Biotechnological Sciences, 'G d'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
| | - Piergustavo De Francesco
- Urology Unit, Azienda Sanitaria Locale 2, San Pio Hospital, Via San Camillo de Lellis, 66054 Vasto, Italy
| | - Luigi Schips
- Department of Medical, Oral and Biotechnological Sciences, 'G d'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
| | - Carmine Di Ilio
- Center for Advanced Studies and Technologies (CAST), University "G. d'Annunzio" of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
| | - Renata Ciccarelli
- Center for Advanced Studies and Technologies (CAST), University "G. d'Annunzio" of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
| | - Patrizia Di Iorio
- Department of Medical, Oral and Biotechnological Sciences, 'G d'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
| | - Stefania Angelucci
- Center for Advanced Studies and Technologies (CAST), University "G. d'Annunzio" of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
- Department of Sciences, 'G d'Annunzio' University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
| |
Collapse
|
2
|
Sleat DE, Maita I, Banach-Petrosky W, Larrimore KE, Liu T, Cruz D, Baker L, Maxfield FR, Samuels B, Lobel P. Elevated levels of tripeptidyl peptidase 1 do not ameliorate pathogenesis in a mouse model of Alzheimer disease. Neurobiol Aging 2022; 118:106-107. [PMID: 35914472 PMCID: PMC11258943 DOI: 10.1016/j.neurobiolaging.2022.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 06/14/2022] [Accepted: 06/30/2022] [Indexed: 10/17/2022]
Abstract
One potential therapeutic strategy for Alzheimer disease (AD) is to promote degradation of amyloid beta (Aβ) and we previously demonstrated that the lysosomal protease tripeptidyl peptidase 1 (TPP1) can degrade Aβ fibrils in vitro. In this study, we tested the hypothesis that increasing levels of TPP1 might promote degradation of Aβ under physiological conditions, slowing or preventing its accumulation in the brain with subsequent therapeutic benefits. We used 2 approaches to increase TPP1 activity in the brain of J20 mice, an AD model that accumulates Aβ and exhibits cognitive defects: transgenic overexpression of TPP1 in the brain and a pharmacological approach employing administration of recombinant TPP1. While we clearly observed the expected AD phenotype of the J20 mice based on pathology and measurement of behavioral and cognitive defects, we found that elevation of TPP1 activity by either experimental approach failed to have any measurable beneficial effect on disease phenotype.
Collapse
Affiliation(s)
- David E Sleat
- Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA; Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers Biomedical Health Sciences, Rutgers University, Piscataway, NJ, USA
| | - Isabella Maita
- Behavioral and Systems Neuroscience, Department of Psychology, Rutgers University-New Brunswick, Piscataway, NJ, USA; Neuroscience Graduate Program, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ, USA
| | | | - Katherine E Larrimore
- Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA
| | - Tonia Liu
- Behavioral and Systems Neuroscience, Department of Psychology, Rutgers University-New Brunswick, Piscataway, NJ, USA
| | - Dana Cruz
- Department of Biochemistry, Weill Cornell Medical College, New York, NY, USA
| | - Lukas Baker
- Department of Biochemistry, Weill Cornell Medical College, New York, NY, USA
| | | | - Benjamin Samuels
- Behavioral and Systems Neuroscience, Department of Psychology, Rutgers University-New Brunswick, Piscataway, NJ, USA; Neuroscience Graduate Program, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ, USA
| | - Peter Lobel
- Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA; Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers Biomedical Health Sciences, Rutgers University, Piscataway, NJ, USA
| |
Collapse
|
3
|
Rosenberg JB, Chen A, Kaminsky SM, Crystal RG, Sondhi D. Advances in the Treatment of Neuronal Ceroid Lipofuscinosis. Expert Opin Orphan Drugs 2019; 7:473-500. [PMID: 33365208 PMCID: PMC7755158 DOI: 10.1080/21678707.2019.1684258] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Accepted: 10/21/2019] [Indexed: 12/27/2022]
Abstract
Neuronal ceroid lipofuscinoses (NCL) represent a class of neurodegenerative disorders involving defective lysosomal processing enzymes or receptors, leading to lysosomal storage disorders, typically characterized by observation of cognitive and visual impairments, epileptic seizures, ataxia, and deterioration of motor skills. Recent success of a biologic (Brineura®) for the treatment of neurologic manifestations of the central nervous system (CNS) has led to renewed interest in therapeutics for NCL, with the goal of ablating or reversing the impact of these devastating disorders. Despite complex challenges associated with CNS therapy, many treatment modalities have been evaluated, including enzyme replacement therapy, gene therapy, stem cell therapy, and small molecule pharmacotherapy. Because the clinical endpoints for the evaluation of candidate therapies are complex and often reliant on subjective clinical scales, the development of quantitative biomarkers for NCLs has become an apparent necessity for the validation of potential treatments. We will discuss the latest findings in the search for relevant biomarkers for assessing disease progression. For this review, we will focus primarily on recent pre-clinical and clinical developments for treatments to halt or cure these NCL diseases. Continued development of current therapies and discovery of newer modalities will be essential for successful therapeutics for NCL. AREAS COVERED The reader will be introduced to the NCL subtypes, natural histories, experimental animal models, and biomarkers for NCL progression; challenges and different therapeutic approaches, and the latest pre-clinical and clinical research for therapeutic development for the various NCLs. This review corresponds to the literatures covering the years from 1968 to mid-2019, but primarily addresses pre-clinical and clinical developments for the treatment of NCL disease in the last decade and as a follow-up to our 2013 review of the same topic in this journal. EXPERT OPINION Much progress has been made in the treatment of neurologic diseases, such as the NCLs, including better animal models and improved therapeutics with better survival outcomes. Encouraging results are being reported at symposiums and in the literature, with multiple therapeutics reaching the clinical trial stage for the NCLs. The potential for a cure could be at hand after many years of trial and error in the preclinical studies. The clinical development of enzyme replacement therapy (Brineura® for CLN2), immunosuppression (CellCept® for CLN3), and gene therapy vectors (for CLN1, CLN2, CLN3, and CLN6) are providing encouragement to families that have a child afflicted with NCL. We believe that successful therapies in the future may involve the combination of two or more therapeutic modalities to provide therapeutic benefit especially as the patients grow older.
Collapse
Affiliation(s)
- Jonathan B Rosenberg
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York
| | - Alvin Chen
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York
| | - Stephen M Kaminsky
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York
| | - Ronald G Crystal
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York
| | - Dolan Sondhi
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York
| |
Collapse
|
4
|
Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease). Sci Rep 2018; 8:15229. [PMID: 30323181 PMCID: PMC6189193 DOI: 10.1038/s41598-018-33449-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 09/12/2018] [Indexed: 12/14/2022] Open
Abstract
Late infantile neuronal ceroid lipofuscinosis (CLN2 disease) is a rare lysosomal storage disorder caused by a monogenetic deficiency of tripeptidyl peptidase-1 (TPP1). Despite knowledge that lipofuscin is the hallmark disease product, the relevant TPP1 substrate and its role in neuronal physiology/pathology is unknown. We hypothesized that untargeted metabolite profiling of cerebrospinal fluid (CSF) could be used as an effective tool to identify disease-associated metabolic disruptions in CLN2 disease, offering the potential to identify biomarkers that inform on disease severity and progression. Accordingly, a mass spectrometry-based untargeted metabolite profiling approach was employed to differentiate CSF from normal vs. CLN2 deficient individuals. Of 1,433 metabolite features surveyed, 29 linearly correlated with currently employed disease severity scores. With tandem mass spectrometry 8 distinct metabolite identities were structurally confirmed based on retention time and fragmentation pattern matches, vs. standards. These putative CLN2 biomarkers include 7 acetylated species - all attenuated in CLN2 compared to controls. Because acetate is the major bioenergetic fuel for support of mitochondrial respiration, deficient acetylated species in CSF suggests a brain energy defect that may drive neurodegeneration. Targeted analysis of these metabolites in CSF of CLN2 patients offers a powerful new approach for monitoring CLN2 disease progression and response to therapy.
Collapse
|